Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 2:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 3,874 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Migraine Disorders
Interventions: Combination Product (sumatriptan succinate / naproxen sodium), Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 26
States / cities: Fresno, California • Newport Beach, California • Santa Monica, California + 23 more

Conditions: Pharmacokinetics
Interventions: Acetylsalicylic acid (Aspirin, BAY1019036), Acetylsalicylic acid (Aspirin, BAYE4465); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Healthy Volunteers
Interventions: GCC-4401C, Rivaroxaban, Placebo; Drug
Lead sponsor: Green Cross Corporation; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Early Phase Clinical Unit _Los Angeles, California

Conditions: Type2 Diabetes, Type 2 Diabetes Mellitus in Obese, Dysglycemia, Microvascular Complications, Brain Structure, Obesity, Childhood, Diabetes in Adolescence, Inflammation, Insulin Resistance, Overweight, Childhood, Cognitive Decline
Interventions: Observational; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 12 Years to 17 Years
Enrollment: 117 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: St Louis, Missouri • Pittsburgh, Pennsylvania

Conditions: Healthy
Interventions: Metformin HCl 500 mg tablets, single dose, CLUCOPHAGE® XR 500 mg tablets, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Streptococcus Infection, Pregnancy
Interventions: Not listed
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 358 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Dystonia, Drug Induced Dystonia, Parkinson Disease, Essential Tremor, Dyskinesias, Myoclonus, Tic Disorders, Torticollis, Ulnar Nerve Entrapment, Temporomandibular Joint Disorders, Dysphonia
Interventions: DystoniaNet-based diagnosis of isolated dystonia; Diagnostic Test
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Marijuana Abuse
Interventions: 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fed condition, 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fasting condition; Drug
Lead sponsor: Aelis Farma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Colitis, Ulcerative
Interventions: SRT2104; Drug
Lead sponsor: Sirtris, a GSK Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 13
States / cities: Anaheim, California • Bristol, Connecticut • Owensboro, Kentucky + 10 more

Conditions: Chlamydia, Gonorrhea, HIV
Interventions: HIV testing, STI/HIV-T, STI/HIV-Plus; Behavioral
Lead sponsor: North Bronx Healthcare Network; Other
Eligibility: 14 Years to 21 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Diabetes Mellitus Type 2
Interventions: GK Activator (2); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 10
States / cities: Chandler, Arizona • Oviedo, Florida • Nampa, Idaho + 7 more

Conditions: Bipolar Disorder, Involutional Depression, Mood Disorder
Interventions: Ethyl Eicosapentaenoic Acid, OmegaBrite; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Intubation Complication
Interventions: Etomidate, Ketamine; Drug
Lead sponsor: South East Area Health Education Center, Wilmington, NC; Other
Eligibility: 18 Years and older
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Healthy
Interventions: LOXO-783; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Hypoglycemia
Interventions: Entry of demographic and medical history data into a deidentified database, Blood sample for DNA analysis, Stool sample for microbiome analysis, Mixed meal tolerance test, Continuous glucose monitoring, activity monitor; Other · Genetic · Diagnostic Test
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Generalized Anxiety Disorder, Bipolar Disorder
Interventions: Ziprasidone, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atrial Arrhythmia, Atrium; Fibrillation, Atrial Tachycardia
Interventions: electrophysiology study and ablation with an Abbott Ablation Catheter; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: Not listed
Enrollment: 200 participants
Timeline: 2022 – 2026
U.S. locations: 20
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Rancho Mirage, California + 16 more

Conditions: Ewing Sarcoma
Interventions: LX-101; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 10 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2033
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Electrical Status Epilepticus of Slow-Wave Sleep
Interventions: Epidiolex 100 mg/mL Oral Solution, Placebo; Drug · Other
Lead sponsor: Northwell Health; Other
Eligibility: 2 Years to 17 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Lake Success, New York

Conditions: Non Small Cell Lung Cancer
Interventions: Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation; Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: New York, New York

Conditions: Trauma, Rapid Sequence Intubation
Interventions: Ketamine, Etomidate, Propofol; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Age-related Cognitive Decline
Interventions: PNF; Other
Lead sponsor: Arizona State University; Other
Eligibility: 65 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Osteoarthritis Post-meniscectomy
Interventions: Bone Marrow Aspirate Concentrate, Standard Meniscectomy; Biological · Procedure
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Schizophrenia
Interventions: Functional Adaptation Skills Training (FAST); Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 40 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: La Jolla, California

Search by objective public record fields.

A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)

Pharmacokinetic Study Comparing Aspirin and Aspirin Granules

A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers

Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D)

A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Fasting Conditions

Rapid Diagnostic Test for Detection of Group B Streptococcus in Pregnancy

Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia

The Effect of Food on the Oral Bioavailability of AEF0117 in Healthy Volunteers

A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis

Project AWARE: Using the Emergency Department (ED) to Prevent Sexually Transmitted Infections (STIs) in Youth

A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.

Omega-3 Fatty Acids in the Treatment of Bipolar Disorder: A Double-Blind, Placebo-Controlled Trial

Evaluating the Hemodynamic Effects of Ketamine Versus Etomidate During Rapid Sequence Intubation

A Study to Evaluate the Effect of Food on LOXO-783 in Healthy Participants

Mechanisms of Hypoglycemia in Patients Without Diabetes

Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder

Abbott Atrial Fibrillation Post Approval Study

RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT

Efficacy of Epidiolex in Patients With Electrical Status Epilepticus of Sleep (ESES).

Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients

Prospective Study of Induction Medications Used in the Trauma RSI

Think FAST Research Study

Autologous Bone Marrow Aspirate Concentrate in Patients Undergoing Meniscectomy

Rehabilitative Training for Older People With Schizophrenia